EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C12H24N2O4 |
| Net Charge | 0 |
| Average Mass | 260.334 |
| Monoisotopic Mass | 260.17361 |
| SMILES | CCCC(C)(COC(N)=O)COC(=O)NC(C)C |
| InChI | InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) |
| InChIKey | OFZCIYFFPZCNJE-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Role: | analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| Applications: | muscle relaxant A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. antispasmodic drug A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| carisoprodol (CHEBI:3419) has role analgesic (CHEBI:35480) |
| carisoprodol (CHEBI:3419) has role antispasmodic drug (CHEBI:53784) |
| carisoprodol (CHEBI:3419) has role muscle relaxant (CHEBI:51371) |
| carisoprodol (CHEBI:3419) is a carbamate ester (CHEBI:23003) |
| Incoming Relation(s) |
| (R)-carisoprodol (CHEBI:59334) is a carisoprodol (CHEBI:3419) |
| (S)-carisoprodol (CHEBI:59336) is a carisoprodol (CHEBI:3419) |
| IUPAC Name |
|---|
| 2-[(carbamoyloxy)methyl]-2-methylpentyl propan-2-ylcarbamate |
| INNs | Source |
|---|---|
| carisoprodol | ChemIDplus |
| carisoprodol | WHO MedNet |
| carisoprodol | WHO MedNet |
| carisoprodolum | ChemIDplus |
| Synonyms | Source |
|---|---|
| (1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester | ChemIDplus |
| (±)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate | ChemIDplus |
| 2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate | ChemIDplus |
| 2-methyl-2-propyltrimethylene carbamate isopropylcarbamate | ChEBI |
| carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester | ChEMBL |
| Carisoprodol | KEGG COMPOUND |
| Brand Names | Source |
|---|---|
| Carisoma | ChEMBL |
| Carisoprodol component of compound | ChEMBL |
| Carisoprodol component of soma compound | ChEMBL |
| Rela | ChEMBL |
| Soma | ChEMBL |
| Manual Xrefs | Databases |
|---|---|
| 509 | DrugCentral |
| C07927 | KEGG COMPOUND |
| Carisoprodol | Wikipedia |
| D00768 | KEGG DRUG |
| DB00395 | DrugBank |
| HMDB0014539 | HMDB |
| LSM-5197 | LINCS |
| US2937119 | Patent |
| Citations |
|---|